Investor's Business Daily on MSN
Why Pharming, a top 3% biotech stock, just took a double-digit beating
Biotech stock Pharming was pummeled Monday after the FDA rejected the company's request to expand the patient pool for Joenja.
The U.S. Food and Drug Administration (FDA) on Friday issued a Complete Response Letter (CRL) to Pharming Group’s (NASDAQ: PHAR) supplemental New Drug Application (sNDA) for Joenja (leniolisib) for ...
On Wednesday, Pharming Group N.V. (NASDAQ:PHAR) revealed topline results of data from its Phase 3 trial evaluating leniolisib in children aged 4 to 11 years with activated phosphoinositide 3-kinase ...
Pharming Group has transitioned from a speculative play to a fundamentally attractive, cash-generating rare disease company. PHAR delivered $376M in FY2025 revenue, up 27% YoY, surpassing guidance, ...
NEW YORK, Feb. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. ("Pharming" or the "Company") (NASDAQ: PHAR). Such investors are advised to ...
Pharming uses living organisms as bioreactors for cheaper, sustainable drug production, but requires navigating complex IP ...
Here's my stab at a possible thesis:Pharming Group (PHAR)- $1.3B MC, $1.3B EV. Valuation for this Netherlands-based rare-disease company seems reasonable as they near $400M annual run rate (trading at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results